Loading stock data…
TFX
$121.77-2.14 (-1.73%)
Market ClosedLast close May 1
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Teleflex Incorporated in the Healthcare sector is trading at $121.77. The stock is currently 13% below its 52-week high of $139.67, remaining 3.1% above its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why TFX maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$121.77
Potential Downside
82%
Whystock Fair Value$21.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Hold
Mean target$132.78+9.0%
Range$115.00 – $147.00
Fundamentals
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
106.78
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Strong income play. Yield provides a meaningful total return floor.
98.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.14%
Volume
Today's trading volume
839,915
Recent News
Teleflex Names Jason Weidman CEO As Valuation Gap And Risks Draw Focus
Teleflex (NYSE:TFX) has appointed Jason Weidman as its next President and CEO. Weidman is scheduled to assume the role on June 8, 2026. Teleflex, trading at $133.3, is coming into this leadership change after mixed share performance. The stock is up 16.0% over the past 30 days and 8.9% year to date, while its 1 year return is a 1.6% decline. Over a longer stretch, the share price shows deeper drawdowns, with 3 year and 5 year returns of 49.8% and 66.4% declines respectively. For investors,...
Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates
Thermo Fisher (TMO) delivered earnings and revenue surprises of +4.67% and +1.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Q4 2024 Earnings Transcript
Participating on today's call are Liam Kelly, Chairman, President and Chief Executive Officer; Thomas Powell, Executive Vice President and Chief Financial Officer; and John Deren, Corporate Vice President and Chief Accounting Officer. Liam, Tom and John will provide prepared remarks, and then we’ll open the call to Q&A.
Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Surpass Estimates
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +20.37% and +6.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?